INGN vs SNWV
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
INGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position with a Current Ratio of 3.12 and very low debt (D/E 0.09), it is unable to translate this into profitability, as evidenced by negative operating margins and stagnant revenue growth of 2%. There is a stark disconnect between the 'Strong Buy' analyst consensus and the fundamental reality of a 5-year price collapse of 88.6%. The stock currently presents as a classic value trap, trading below book value but lacking the growth catalysts necessary for a reversal.
SNWV exhibits severe fundamental weakness, highlighted by a weak Piotroski F-Score of 3/9 and an extreme valuation gap. The stock is trading at $20.61, which is astronomically higher than its Graham Number ($1.32) and Intrinsic Value ($2.87). While revenue growth is strong at 26.8%, the company is burdened by a dangerous Debt/Equity ratio of 14.19 and a Price/Book ratio of 109.63. Despite 'strong buy' analyst ratings, the combination of bearish insider selling and a negative forward P/E suggests a high risk of a significant correction.
Compare Another Pair
Related Comparisons
INGN vs SNWV: Head-to-Head Comparison
This page compares Inogen, Inc. (INGN) and SANUWAVE Health, Inc. (SNWV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.